1. 208 Long-term efficacy of erenumab in patients with chronic migraine who failed ≥3 prior prophylactic treatments. Issue 6 (27th May 2022) Authors: Weatherall, Mark; Gantenbein, Andreas; Ritter, Shannon; Snellman, Josefin; Klatt, Jan Klatt; Mikol, Daniel Journal: Journal of neurology, neurosurgery and psychiatry Issue: Volume 93:Issue 6(2022) Page Start: A73 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A Randomized Trial Evaluating Various Administration Routes of Natalizumab in Multiple Sclerosis. (3rd March 2016) Authors: Plavina, Tatiana; Fox, Edward J.; Lucas, Nisha; Muralidharan, Kumar Kandadi; Mikol, Daniel Journal: Journal of clinical pharmacology Issue: Volume 56:Number 10(2016) Page Start: 1254 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Exploring potential mechanisms of action of natalizumab in secondary progressive multiple sclerosis. (January 2016) Authors: Sellebjerg, Finn; Cadavid, Diego; Steiner, Deborah; Villar, Luisa Maria; Reynolds, Richard; Mikol, Daniel Journal: Therapeutic advances in neurological disorders Issue: Volume 9:Number 1(2016:Jan.) Page Start: 31 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Phase 3, randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of erenumab (amg 334) in migraine prevention: primary results of the strive trial. Issue 5 (8th May 2017) Authors: Goadsby, Peter J; Reuter, Uwe; Bonner, Jo; Broessner, Gregor; Hallstrom, Yngve; Zhang, Feng; Sapra, Sandhya; Picard, Hernan; Mikol, Daniel; Lenz, Robert Journal: Journal of neurology, neurosurgery and psychiatry Issue: Volume 88:Issue 5(2017) Page Start: e1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Reducing the physical, social, and emotional impact of episodic migraine: Results from erenumab STRIVE and ARISE phase III randomized trials. Issue 2 (8th February 2022) Authors: Kawata, Ariane K.; Ladd, Mary Kate; Lipton, Richard B.; Buse, Dawn C.; Bensink, Mark; Shah, Shweta; Hareendran, Asha; Mannix, Sally; Mikol, Daniel Journal: Headache Issue: Volume 62:Issue 2(2022) Page Start: 159 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patients. (10th October 2017) Authors: Plavina, Tatiana; Muralidharan, Kumar Kandadi; Kuesters, Geoffrey; Mikol, Daniel; Evans, Karleyton; Subramanyam, Meena; Nestorov, Ivan; Chen, Yi; Dong, Qunming; Ho, Pei-Ran; Amarante, Diogo; Adams, Alison; De Sèze, Jerome; Fox, Robert; Gold, Ralf; Jeffery, Douglas; Kappos, Ludwig; Montalban, Xavi... Journal: Neurology Issue: Volume 89:Number 15(2017) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. Issue 6 (June 2017) Authors: Tepper, Stewart; Ashina, Messoud; Reuter, Uwe; Brandes, Jan L; Doležil, David; Silberstein, Stephen; Winner, Paul; Leonardi, Dean; Mikol, Daniel; Lenz, Robert Journal: Lancet neurology Issue: Volume 16:Issue 6(2017:Jun.) Page Start: 425 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. The EDSS-Plus, an improved endpoint for disability progression in secondary progressive multiple sclerosis. (January 2017) Authors: Cadavid, Diego; Cohen, Jeffrey A; Freedman, Mark S; Goldman, Myla D; Hartung, Hans-Peter; Havrdova, Eva; Jeffery, Douglas; Kapoor, Raj; Miller, Aaron; Sellebjerg, Finn; Kinch, Deborah; Lee, Sophia; Shang, Shulian; Mikol, Daniel Journal: Multiple sclerosis Issue: Volume 23:Number 1(2017) Page Start: 94 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗